Abstract
A 24-hour hospitalization for TIA could be cost-effective simply by increasing the likelihood that patients will receive tissue plasminogen activator if a stroke occurs. The authors performed a cost-utility analysis of 24-hour hospitalization for patients diagnosed with recent TIA. The overall cost-effectiveness ratio was 55,044 dollars per quality-adjusted life-year, a value considered borderline cost-effective. For patients with higher risk of stroke, admission was cost-effective.
MeSH terms
-
Academic Medical Centers / economics
-
Academic Medical Centers / statistics & numerical data
-
Cost-Benefit Analysis
-
Decision Trees
-
Emergency Service, Hospital / economics
-
Emergency Service, Hospital / statistics & numerical data
-
Fibrinolytic Agents / economics
-
Fibrinolytic Agents / therapeutic use*
-
Hospitalization / economics*
-
Hospitalization / statistics & numerical data
-
Humans
-
Ischemic Attack, Transient / drug therapy*
-
Ischemic Attack, Transient / economics*
-
Markov Chains
-
Models, Statistical
-
Quality-Adjusted Life Years
-
Registries
-
Risk Factors
-
Stroke / prevention & control*
-
Thrombolytic Therapy / economics*
-
Thrombolytic Therapy / standards
-
Tissue Plasminogen Activator / economics
-
Tissue Plasminogen Activator / therapeutic use*
Substances
-
Fibrinolytic Agents
-
Tissue Plasminogen Activator